Banned in Boston

April 6, 2009 by Chris Markuns

Massachusetts enacted the nation's strictest law governing industry payments to physicians. What does the so-called "gift ban" mean for the Commonwealth's medical devices sector?

Say goodbye to the promotional pen

Pharma is sexy. Big drugs, big money, big news. In the life sciences arena, perhaps only biotech commands a higher political and public profile.

So it isn’t surprising that the medical device industry’s groundbreaking inclusion in Massachusetts’ new code of conduct garnered relatively little attention.

But the new rules governing industry payments to physicians — the so-called "gift ban" — include provisions aimed at curbing what some call undue and improper influence by medical device manufacturers.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Features

Blame the medical device tax and the U.S. regulatory environment for the slump in investment in early-stage medical technologies, Silicon Valley Bank's Ben Johnson tells MassDevice.com.

Halyard Health, the publicly traded, $1.6 billion spinout of Kimberly-Clark's medical device business, is slated to go live in November, soon-to-be COO Chris Lowery tells MassDevice.com.

David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.

Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.

MassDevice.com brought together 4 of the most influential leaders in medtech to discuss the future of the industry on July 15, 2014 at DeviceTalks Boston.